Clinical and Pathologic Data
| Patient no. | Age (y) | Sex | Pathology | SUV | Glut 1 | HKI | HK II | HK III |
|---|---|---|---|---|---|---|---|---|
| 1 | 40 | M | HCC, G II–III | 3.3 | − | − | + | − |
| 2 | 54 | M | HCC, G III | 3.9 | − | − | + | − |
| 3 | 54 | M | HCC, G II–III | 5.6 | − | Weak | + | Weak |
| 4 | 50 | M | HCC, G III, HB cirrhosis | 3.2 | − | − | + | − |
| 5 | 58 | F | HCC, G II–III, HB cirrhosis | 7.3 | − | − | + | − |
| 6 | 63 | F | HCC, G III, HB cirrhosis | 3.8 | − | − | + | − |
| 7 | 53 | F | Intermediate HCC, HB cirrhosis | 10.0 | + | − | + | − |
| 8 | 41 | F | Cholangiocarcinoma, MD | 13.4 | + | − | − | − |
| 9 | 48 | F | Cholangiocarcinoma, MD | 9.1 | + | − | − | − |
| 10 | 52 | M | Cholangiocarcinoma, MD | 13.5 | + | − | − | Weak |
| 11 | 47 | F | Cholangiocarcinoma, PD | 8.7 | + | − | − | − |
| 12 | 73 | M | Cholangiocarcinoma, MD | 6.2 | + | − | Weak | − |
| 13 | 75 | M | Cholangiocarcinoma, PD | 12.8 | + | − | − | − |
| 14 | 54 | F | Cholangiocarcinoma, PD | 17.4 | + | − | − | Weak |
G = grade; HB = hepatitis B; MD = moderately differentiated; PD = poorly differentiated.